Vertex Pharmaceuticals

Open: 418.38 Close: 415.51 Change: -2.87

Is Vertex Pharmaceuticals Company Inc a good investment? This what an AI found.

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, price, company, stock, Incorporated, VRTX, and the most common words in the summary are: vertex, pharmaceutical, stock, market, vrtx, price, news, . One of the sentences in the summary was: Average price target for Vertex Pharmaceuticals comes to $447.00. Other searches …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Average price target for Vertex Pharmaceuticals comes to $447.00. The current share price is $416.02 USD today. There is no upcoming split for the company.

Today's News

Global Equity Strategy featured stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the fourth quarter 2023 investor letter. Headquartered in Boston, Massachusetts, Vertex. Incorporated has a market capitalization of $109.015 billion. Average price target for Vertex Pharmaceuticals comes to $447.00. The average price target is 7.44% higher than that of 23 analysts. The current share price is $416.02. Vertex Pharmaceuticals stock price is 416.02 USD today. The Vertex pharmaceuticals stock quote is 416.02USD. The company is a publicly traded company. The latest price target for Vertex Pharmaceuticals ( NASDAQ : VRTX ) was reported by Cantor Fitzgerald on Tuesday, February 6, 2024. There is no upcoming split for the company. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) filed its yearly result this time last week. Revenues of US$9.9b and statutory earnings per share were in line with analyst estimates. 27 analysts are now forecasting revenues of US $10.7b. Vertex Pharmaceuticals (VRTX) 4Q adjusted EPS came in at $4.... Other symbols: NXPI PLTR. Vertex Pharmaceuticals Inc. is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. The European Commission (EC) approves our treatment for #SickleCellDisease and #BetaThalassemia for the European Union.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

The game is changing. There is a new strategy to evaluate Vertex Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, price, company, stock, Incorporated, VRTX, and the most common words in the summary are: vertex, pharmaceutical, stock, market, vrtx, price, news, . One of the sentences in the summary was: Average price target for Vertex Pharmaceuticals comes to $447.00. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #market #vrtx #price #news.